Poging GOUD - Vrij
US generics, domestic market to drive pharma cos' Q4 sales growth
Mint New Delhi
|April 29, 2025
Analysts anticipate higher sales of Revlimid to drive growth for US-focused firms such as Sun Pharma in Q4
Pharma companies are expected to report healthy revenue growth of 11-13% in the fourth quarter of FY25, driven by strong traction in niche US generic drugs, steady domestic performance in a seasonally weak quarter and higher sales of a blockbuster cancer drug in the US before its distribution exclusivity ends next year, analysts said.
Uncertainties over US tariffs and the end of the limited competition period for generic Revlimid in the US loom in the months ahead. However, analysts anticipate higher sales of Revlimid to drive growth for US-focused companies such as Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd and Sun Pharmaceutical Industries Ltd in Q4 and the first few quarters of the next fiscal.
Dit verhaal komt uit de April 29, 2025-editie van Mint New Delhi.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Mint New Delhi
Mint New Delhi
How high credit card utilization affects your score: a quick guide
I had a ₹1 lakh credit card bill but repaid ₹40,000; ₹60.000 is due. Will it hurt my credit score? Can I take a personal loan to clear it? Will it affect my score and future loan applications? - Name withheld on request
1 mins
November 20, 2025
Mint New Delhi
Incentives drive each and every participant in all capital markets
Investors must note that everyone is motivated by self-interest whether we know the specifics or not
4 mins
November 20, 2025
Mint New Delhi
India's financial boom: Let's keep progress real
Record funds raised for shareholder exits rather than fresh investment go against the spirit of IPOs. The bigger issue is that the financial world must stay in sync with the real economy
2 mins
November 20, 2025
Mint New Delhi
Meta's big court win
Social media major Meta has won big relief as a US judge ruled in its favour in an antitrust case filed by the US Federal Trade Commission (FTC) that could have forced it to spin off Instagram and WhatsApp.
1 min
November 20, 2025
Mint New Delhi
xAI in talks to raise $15 billion in fresh equity
Elon Musk's artificial-intelligence startup xAI is in advanced talks to raise $15 billion in fresh equity at a valuation of $230 billion, The Wall Street Journal reported on Tuesday.
1 min
November 20, 2025
Mint New Delhi
AYURVEDIC HOSPITAL CARE: WHY INSURERS PUSH BACK—AND HOW TO WIN CLAIMS
Over the past few years, a friend has undergone Ayurvedic treatment for fluctuating blood pressure at a Kerala hospital. The insurer had routinely covered a week of hospitalization, but this time rejected the claim, arguing the annual treatment appeared more like rest than medical necessity. Ayurvedic claims are becoming harder to get approved.
3 mins
November 20, 2025
Mint New Delhi
Fabindia-Biome row now in arbitration
The founders of personal care company Biome Life Sciences India Pvt. Ltd on Wednesday told the Delhi high court that they were withdrawing their petition against parent Fabindia Ltd over share valuations.
2 mins
November 20, 2025
Mint New Delhi
A fresh perspective on abstraction in art
A new exhibition in Mumbai showcases different approaches to abstraction by artists like Zarina, Seher Shah and Mehlli Gobhai
3 mins
November 20, 2025
Mint New Delhi
In a new avatar, Zomato steps into India's top 25 brands
Its brand value jumped 69% year-on-year, Kantar’s BrandZ report for 2025 shows
1 mins
November 20, 2025
Mint New Delhi
Bank-funded acquisitions won’t displace private credit
The Reserve Bank of India's (RBI) draft framework for bank-led acquisition finance marks a decisive policy turn: Indian banks can now enter the acquisition finance market within a clear perimeter, reshaping the competitive dynamics between banks and private credit funds.
3 mins
November 20, 2025
Listen
Translate
Change font size